Pharmacological and clinical profile of moexipril: A concise review

Angiotensin-converting enzyme (ACE) inhibitors ore effective and safe antihypertensive drugs, with the exception of the rare occasion of angioedema. These drugs hove demonstrated additional cardiovascular protective effects to their blood pressure lowering, and their combination with the diuretic hydrochlorothiozide potentiates their antihypertensive effectiveness. Moexipril is a long-acting ACE inhibitor suitable for once-daily administration, and like some ACE-inhibitors, moexipril is a prodrug and needs to be hydrolyzed in the liver in to its active carboxylic metabolite, moexiprilat, to become effective. Moexipril alone and in combination with low-dose hydrochlorothiazide has been shown in clinical trials to be effective in lowering blood pressure and be well tolerated and safe given in single daily closes. In this review,, the pharmacological profile of this drug and its clinical usefulness are discussed.